TickerFacts.

Sera Prognostics, Inc. (SERA): EBITDA

Operating income plus depreciation and amortization for the same annual period and currency, computed by TickerFacts from the filed figures. Not the company's adjusted EBITDA; a year without both inputs is left out.

-$35.56M
Year ended 2025-12-31
-$36.43M
Trailing 12 months to 2026-06-30
2020-12-31: -$17.08M2021-12-31: -$34.74M2022-12-31: -$44.90M2023-12-31: -$38.92M2024-12-31: -$35.80M2025-12-31: -$35.56M-$35.56M
2020-12-31 EBITDA (USD) 2025-12-31
Period endedEBITDAChange YoYSource filing
2025-12-31-$35.56Mn/m2026-03-18, From 2025-01-01
2024-12-31-$35.80Mn/m2026-03-18, From 2024-01-01
2023-12-31-$38.92Mn/m2025-03-19, From 2023-01-01
2022-12-31-$44.90Mn/m2024-03-20, From 2022-01-01
2021-12-31-$34.74Mn/m2023-03-22, From 2021-01-01
2020-12-31-$17.08Mn/a2022-03-29, From 2020-01-01

EBITDA at similar companies

Companies with the same SEC industry code (Services-Medical Laboratories), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedEBITDAChange YoY
Sera Prognostics, Inc. (SERA)2025-12-31-$35.56Mn/m
Aclarion, Inc. (ACON)2025-12-31-$6.82Mn/m
American Shared Hospital Services (AMS)2025-12-31$2.13M-36.9%
Exagen Inc. (XGN)2025-12-31-$11.97Mn/m
Personalis, Inc. (PSNL)2025-12-31-$78.01Mn/m
Biodesix Inc (BDSX)2025-12-31-$22.20Mn/m
BillionToOne, Inc. (BLLN)2025-12-31$22.92Mn/m
Fulgent Genetics, Inc. (FLGT)2025-12-31-$66.97Mn/m
Castle Biosciences Inc (CSTL)2025-12-31-$2.04Mn/m

Compare SERA, ACON, AMS, XGN side by side · Screen every company in Services-Medical Laboratories ↗